Table 3.
Total (n = 105) | Phase 1 (n = 36) | Phase 2 (n = 24) | Phase 3 (n = 45) | p | |
---|---|---|---|---|---|
Any postoperative complication | 6 (5.7) | 3 (8.3) | 2 (8.3) | 1 (2.2) | 0.410 |
Minor complications, yes, n (%) Clavien-Dindo Grade-1 Clavien-Dindo Grade-2 Major complications, yes, n (%) Clavien-Dindo Grade-3a Grade-3b |
3 (2.9) 1 (1) 1 (1) 1 (1) |
1 (2.8) 1 (2.8) 1 (2.8) 0 (0) |
1 (4.2) 0 (0) 0 (0) 1 (4.2) |
1 (2.2) 0 (0) 0 (0) 0 (0) |
0.482 |
CCI® score, median (range) | 0 (0–33.7) | 0 (0–26.2) | 0 (0–33.7) | 0 (0–8.7) | 0.397 |
SSE*, n (%) SSI, superficial, n (%) SSO, seroma, n (%) |
1 (1) 1 (1) 1 (1) |
1 (2.8) 1 (2.8) 1 (2.8) |
0 (0) 0 (0) 0 (0) |
0 (0) 0 (0) 0 (0) |
0.380 |
SSO/SSI-PI, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | NA |
CCI comprehensive complication index® (University of Zurich, Zurich, Switzerland), SSEs surgical site events, SSI surgical site infection, SSO surgical site occurrences, SSO/SSI-PI surgical site occurrence or surgical site infection procedural intervention
*Seroma occurred in one patient and became infected in subsequent follow-up, Morale-Conde grade 3E [11]